| Literature DB >> 23818621 |
Amit Sharma1, Ross C Larue, Matthew R Plumb, Nirav Malani, Frances Male, Alison Slaughter, Jacques J Kessl, Nikolozi Shkriabai, Elizabeth Coward, Sriram S Aiyer, Patrick L Green, Li Wu, Monica J Roth, Frederic D Bushman, Mamuka Kvaratskhelia.
Abstract
The selection of chromosomal targets for retroviral integration varies markedly, tracking with the genus of the retrovirus, suggestive of targeting by binding to cellular factors. γ-Retroviral murine leukemia virus (MLV) DNA integration into the host genome is favored at transcription start sites, but the underlying mechanism for this preference is unknown. Here, we have identified bromodomain and extraterminal domain (BET) proteins (Brd2, -3, -4) as cellular-binding partners of MLV integrase. We show that purified recombinant Brd4(1-720) binds with high affinity to MLV integrase and stimulates correct concerted integration in vitro. JQ-1, a small molecule that selectively inhibits interactions of BET proteins with modified histone sites impaired MLV but not HIV-1 integration in infected cells. Comparison of the distribution of BET protein-binding sites analyzed using ChIP-Seq data and MLV-integration sites revealed significant positive correlations. Antagonism of BET proteins, via JQ-1 treatment or RNA interference, reduced MLV-integration frequencies at transcription start sites. These findings elucidate the importance of BET proteins for MLV integration efficiency and targeting and provide a route to developing safer MLV-based vectors for human gene therapy.Entities:
Keywords: retroviral gene therapy; virus–host interactions
Mesh:
Substances:
Year: 2013 PMID: 23818621 PMCID: PMC3718171 DOI: 10.1073/pnas.1307157110
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205